Journal article
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial.
- Abstract:
-
BACKGROUND: Evidence is scarce for the effectiveness of therapies for oesophageal cancer progressing after chemotherapy, and no randomised trials have been reported. We aimed to compare gefitinib with placebo in previously treated advanced oesophageal cancer. METHODS: For this phase 3, parallel, randomised, placebo-controlled trial, eligible patients were adults with advanced oesophageal cancer or type I/II Siewert junctional tumours, histologically confirmed squamous-cell carcinoma or adenoc...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Accepted manuscript, pdf, 1.2MB, Terms of use)
-
- Publisher copy:
- 10.1016/s1470-2045(14)70024-5
Authors
Funding
Bibliographic Details
- Publisher:
- Elsevier
- Journal:
- Lancet. Oncology More from this journal
- Volume:
- 15
- Issue:
- 8
- Pages:
- 894-904
- Publication date:
- 2014-06-17
- DOI:
- EISSN:
-
1474-5488
- ISSN:
-
1470-2045
Item Description
- Language:
-
English
- Keywords:
-
- Pubs id:
-
pubs:470727
- UUID:
-
uuid:19906f31-3e43-443f-8b17-12f92a865d95
- Local pid:
-
pubs:470727
- Source identifiers:
-
470727
- Deposit date:
-
2014-07-02
Terms of use
- Copyright holder:
- Elsevier
- Copyright date:
- 2014
- Notes:
- Copyright © 2014 Elsevier Ltd. All rights reserved. This is the accepted manuscript version of the article. The final version is available online from Elsevier at: [10.1016/S1470-2045(14)70024-5].
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record